Related Experiment Video

Updated: Jul 17, 2026

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck

C W M Reuter1, M A Morgan, A Eckardt

  • 1Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. christophereuter@yahoo.com

British Journal of Cancer
|January 17, 2007
PubMed

Insights

New therapies targeting the epidermal growth factor receptor (EGFR) show promise for treating head and neck squamous cell carcinoma (SCCHN). Targeting EGFR may improve outcomes for patients with this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Squamous cell carcinoma of the head and neck (SCCHN) has seen limited survival improvements despite advances in traditional treatments like surgery, chemotherapy, and radiotherapy.
  • Epidermal growth factor receptor (EGFR) is overexpressed in SCCHN tumors, correlating with a poorer prognosis, highlighting its potential as a therapeutic target.

Purpose of the Study:

  • To review the efficacy of novel therapies targeting the epidermal growth factor receptor (EGFR) in patients with squamous cell carcinoma of the head and neck (SCCHN).
  • To explore the potential of molecularly targeted treatment strategies for improving outcomes in SCCHN.

Main Methods:

  • Review of current research and clinical trials on novel therapies targeting EGFR in SCCHN.
  • Analysis of the role of EGFR overexpression and aberrant signaling in SCCHN pathogenesis.

Main Results:

  • Novel therapies targeting EGFR, including anti-EGFR antibodies and EGFR tyrosine kinase inhibitors, are under investigation for SCCHN.
  • These targeted therapies aim to inhibit aberrant EGFR activity and signaling pathways crucial for SCCHN growth and survival.

Conclusions:

  • Targeting EGFR represents a promising strategy to overcome the limitations of conventional therapies in SCCHN.
  • Further research and clinical evaluation of EGFR-targeted therapies are essential to improve patient prognosis and survival rates in SCCHN.

More Related Videos

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.